Target intelligence / Profile preview

Class I PDZ-domain proteins (Class I PDZ)

Target
Class I PDZ
Molecular classification
Scaffolding protein, Protein-protein interaction domain, Signaling protein
01

Overview

Class I PDZ-domain proteins are a diverse group of scaffolding molecules defined by the presence of one or more PDZ domains that specifically recognize C-terminal peptide motifs with the consensus sequence Ser/Thr-X-Φ, where Φ represents a hydrophobic residue [1, 2]. These proteins are essential for the spatial organization of signaling pathways, as they facilitate the assembly of multi-protein complexes at specific subcellular locations, such as the postsynaptic density in neurons or tight junctions in epithelial cells [1, 3]. By anchoring receptors, ion channels, and enzymes to the cytoskeleton, Class I PDZ proteins regulate signal transduction efficiency and maintain cellular architecture and polarity [2, 5]. In pathological contexts, these proteins are often implicated in the progression of cancer through the loss of cell polarity or the over-activation of growth signaling, and in neurological conditions like ischemic stroke, where they mediate excitotoxic signaling complexes [4, 5]. Therapeutic targeting of Class I PDZ domains primarily focuses on the development of small molecules or peptidomimetics, such as Nerinetide, which disrupt specific protein-protein interactions to prevent disease-associated signaling without affecting the global function of the protein [4].

Other names
PSD-95/DlgA/zo-1 domain proteinsGLGF domain proteinsDHR domain proteinsClass I Postsynaptic density-95/Discs large/Zonula occludens-1 domain proteins
02

Mechanism of action

Inhibition of protein-protein interactions by competitive binding to the PDZ domain, disrupting the assembly of signaling complexes.

03

Biological functions

Signal transductionCell polaritySynaptic plasticityIon channel anchoringProtein trafficking
04

Disease associations

StrokeCancerCystic fibrosisNeuropathic painViral infection
05

Safety considerations

Off-target binding due to high structural homology among PDZ domainsDisruption of essential physiological scaffoldingPotential for systemic toxicity given broad tissue distribution
06

Interacting drugs

Nerinetide

3 more in the full profile.

07

Biomarkers

PSD-95 expression levelsNHERF1 phosphorylation statusScribble membrane localization

Beyond the preview

Go deeper on Class I PDZ-domain proteins (Class I PDZ).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Class I PDZ-domain proteins (Class I PDZ).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call